Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2014 by Massachusetts General Hospital.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Carolyn N. Krasner, MD, Massachusetts General Hospital Identifier:
First received: July 25, 2012
Last updated: January 22, 2014
Last verified: January 2014

July 25, 2012
January 22, 2014
April 2012
April 2016   (final data collection date for primary outcome measure)
Progression Free Survival [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Progression free survival at 6 months (PFS6) using RECIST 1.1
Same as current
Complete list of historical versions of study NCT01652079 on Archive Site
  • Response Rate [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Response Rate (CR+PR) using RECIST 1.1
  • Assessment of Toxicity [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    Assessment of toxicity
  • Analysis of biopsies [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Analysis of ovarian tumor biopsies and ascites of the presence or absence of CRLX101 or the active drug, camptothecin
Same as current
Not Provided
Not Provided
CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer
A Phase II, 2-stage Trial of CRLX101 in Combination With Bevacizumab in Recurrent Platinum-Resistant Ovarian, Tubal and Peritoneal Cancer

This research study is a Phase II clinical trial. In addition to studying safety, Phase II clinical trials test if the investigational drug is effective and whether the drug works in treating a specific cancer. "Investigational" means that the drug is still being studied and that research doctors are trying to find out more about it-such as the safest dose to use, the side effects it may cause, and if the drug is effective for treating different types of cancer. It also means that the FDA (the U.S. Food and Drug Administration) has not yet approved CRLX101 for your type of cancer.

Camptothecin is a chemical extracted from plants that is the basis for the standard FDA-approved chemotherapy drugs irinotecan and topotecan. Camptothecin works by interfering with the way cells divide and multiply. The investigational drug CRLX101 is a formulation of camptothecin and a large molecule (nanoparticle)that appears to allow more of the camptothecin to get into tumors and stay in tumors. The persistence of the CRLX101 in the tumor may increase the probability that the tumor cells will be damaged.

CRLX101 has been well tolerated in the laboratory and in participants with different kinds of cancer.

Bevacizumab (Avastin) is a VEGF inhibitor which has activity in many kinds of cancer. Bevacizumab has been successfully combined with many chemotherapy partners.

It has been hypothesized that the combination of bevacizumab with CRLX101 might have unique clinical activity in combination in the treatment of this disease due to the simultaneous inhibition of distinct steps along the HIF → (CAIX) → VEGF → VEGFR2 pathway. Specifically, it is hypothesized that CRLX101-mediated inhibition of HIF-1α carries with it the potential to interrupt hypoxia and HIF-1α-associated resistance to VEGFR inhibitors. It is hoped that this combination will work to treat your type of cancer.

You will receive CRLX101 and bevacizumab through an intravenous (IV) infusion once every 14 days. Each cycle is 28 days. You will continue to receive both drugs until you and/or the research doctor decides it may not be in your best interest to continue.

You will receive premedication including decadron, zantac and benadryl to help prevent an allergic reaction and nausea prior to your CRLX101 infusion.You will also receive IV fluid before and after the study drug administration to keep you hydrated. It will be important for you to drink water regularly in between study visits.You will be treated as an outpatient. At every clinic visit, you will undergo the following assessments: Medical history, physical examination, vital signs, performance status, routine blood tests, urine tests, assessment for any new side effects, CT evaluation (every 8 weeks).

You will have an end of study visit within 30 days of your last dose.

Phase 2
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer
Drug: CRLX101
q 14 days
Experimental: Treatment Arm
Intervention: Drug: CRLX101
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
Not Provided
April 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically or cytologically confirmed epithelial ovarian, tubal or primary peritoneal cancer
  • Measurable disease
  • May have received up to 2 prior cytotoxic chemotherapy
  • Life expectancy of greater than 3 months

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Prior camptothecin, prior VEFG inhibitors
  • Gross hematuria
  • Chemotherapy or radiotherapy within 4 weeks of study entry
  • uncontrolled HTN
  • Receiving other study agents
  • History of allergic reaction to compounds of similar chemical or biologic composition to topotecan or irinotecan
  • Known brain metastases
  • History of a different malignancy within the previous 2 years
  • Intercurrent illness
  • HIV positive on combination antiretroviral therapy
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Carolyn N. Krasner, MD, Massachusetts General Hospital
Massachusetts General Hospital
Not Provided
Not Provided
Massachusetts General Hospital
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP